Virbac SA
PAR:VIRP

Watchlist Manager
Virbac SA Logo
Virbac SA
PAR:VIRP
Watchlist
Price: 368 EUR -0.27% Market Closed
Market Cap: 3.1B EUR
Section:
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one VIRP stock under the Base Case scenario is 431.7 EUR. Compared to the current market price of 368 EUR, Virbac SA is Undervalued by 15%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VIRP Relative Value
Base Case
431.7 EUR
Undervaluation 15%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.7
P/S
P/S
Price to Sales
1.7
vs History
85
vs Industry
54
Median 3Y
1.9
Median 5Y
2
Industry
2.6
Forward
2.1
More Details
6.5
P/E
P/E
Price to Earnings
6.5
vs History
87
vs Industry
27
Median 3Y
19.1
Median 5Y
19.2
Industry
21.8
Forward
19.3
More Details
15.7
P/OCF
P/OCF
Price to OCF
15.7
vs History
65
vs Industry
31
Median 3Y
17
Median 5Y
18.8
Industry
16.7
More Details
2 269.3
P/FCFE
P/FCFE
Price to FCFE
2 269.3
vs History
0
vs Industry
33
Median 3Y
30.4
Median 5Y
30.1
Industry
22.7
More Details
2.9
P/B
P/B
Price to Book Value
2.9
vs History
57
vs Industry
30
Median 3Y
2.7
Median 5Y
3
Industry
2.3
More Details
1.8
EV/S
EV/S
Enterprise Value to Sales
1.8
vs History
74
vs Industry
52
Median 3Y
1.9
Median 5Y
2
Industry
2.9
Forward
2.1
More Details
3.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.3
vs History
68
vs Industry
61
Median 3Y
3.4
Median 5Y
3.9
Industry
5.5
More Details
5.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
5.2
vs History
87
vs Industry
33
Median 3Y
9.6
Median 5Y
10.4
Industry
13
Forward
10.7
More Details
5.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
5.8
vs History
85
vs Industry
33
Median 3Y
12.2
Median 5Y
13.1
Industry
16.6
Forward
13.5
More Details
16.3
EV/OCF
EV/OCF
Enterprise Value to OCF
16.3
vs History
53
vs Industry
31
Median 3Y
16.2
Median 5Y
17.9
Industry
15.8
More Details
35.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
35.8
vs History
39
vs Industry
22
Median 3Y
31.1
Median 5Y
33.2
Industry
19.1
More Details
2.1
EV/IC
EV/IC
Enterprise Value to IC
2.1
vs History
53
vs Industry
38
Median 3Y
2
Median 5Y
2.2
Industry
1.9
More Details

Multiples Across Competitors

VIRP Competitors Multiples
Virbac SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Virbac SA
PAR:VIRP
3.1B EUR 1.7 6.5 5.2 5.8
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55.2 37.1 39.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
497.9B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
244.7B CHF 4 26 11.7 13.2
UK
AstraZeneca PLC
LSE:AZN
216.7B GBP 4.9 30.5 108.5 158.8
US
Merck & Co Inc
NYSE:MRK
260.7B USD 4.1 13.7 9.7 11.6
CH
Novartis AG
SIX:NOVN
200.5B CHF 4.5 17.3 11 14.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.6 9.5 11
IE
Endo International PLC
LSE:0Y5F
202B USD 87.1 -69.1 320.4 803.4
US
Pfizer Inc
NYSE:PFE
146.4B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
FR
Virbac SA
PAR:VIRP
Average P/E: 22
6.5
11%
0.6
US
Eli Lilly and Co
NYSE:LLY
55.2
50%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
26
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.5
38%
0.8
US
Merck & Co Inc
NYSE:MRK
13.7
15%
0.9
CH
Novartis AG
SIX:NOVN
17.3
18%
1
DK
Novo Nordisk A/S
CSE:NOVO B
13.6
7%
1.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.1 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
31%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Virbac SA
PAR:VIRP
Average EV/EBITDA: 398.5
5.2
6%
0.9
US
Eli Lilly and Co
NYSE:LLY
37.1
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
8%
2
CH
Roche Holding AG
SIX:ROG
11.7
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
108.5
10%
10.9
US
Merck & Co Inc
NYSE:MRK
9.7
7%
1.4
CH
Novartis AG
SIX:NOVN
11
6%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
9.5
6%
1.6
IE
E
Endo International PLC
LSE:0Y5F
320.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Virbac SA
PAR:VIRP
Average EV/EBIT: 1 708.3
5.8
6%
1
US
Eli Lilly and Co
NYSE:LLY
39.7
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
14%
1.5
CH
Roche Holding AG
SIX:ROG
13.2
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
158.8
22%
7.2
US
Merck & Co Inc
NYSE:MRK
11.6
9%
1.3
CH
Novartis AG
SIX:NOVN
14.2
12%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
11
6%
1.8
IE
E
Endo International PLC
LSE:0Y5F
803.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
10%
1

See Also

Summary
VIRP intrinsic value, competitors valuation, and company profile.
DCF Valuation
VIRP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VIRP stock valuation using valuation multiples.
Wall Street Estimates
VIRP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VIRP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 299,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.